Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

2 Nov 2017 07:00

RNS Number : 3058V
Elektron Technology PLC
02 November 2017
 

Elektron Technology plc

("Elektron", the "Group" or the "Company")

 

Trading Update

 

Elektron Technology plc (AIM: EKT), the global technology group, is pleased to provide an update on trading for the third quarter ended 31 October 2017.

Sales

Group trading was strong in Q3 with sales increasing 34% compared to the same period last year to £8.6m (2017: £6.4m). Year to date sales have increased by 15% to £22.9m (2017: £19.9m).

Bulgin achieved record quarterly sales of £7.8m in Q3, 37% higher than the same period last year (2017: £5.7m) following successful manufacturing scale-up to convert the unprecedented order demand in H1 into sales. The board expects that Bulgin sales will revert to more normal levels through Q4.

 

Sales £m

Unaudited

Unaudited

Q3 2018

Q3 2017

YTD 2018

YTD 2017

Bulgin

7.8

5.7

20.3

17.4

IMC (Queensgate and Elektron Eye Technology)

0.7

0.7

2.3

2.3

Checkit

0.1

0.3

0.2

 

Total

 

8.6

 

6.4

 

22.9

 

19.9

 

Orders

Group order intake remains well ahead of prior year, with all business segments demonstrating growth.

Bulgin and IMC orders are both 20% above prior year levels year to date.

Checkit has continued to build recurring revenue streams and total contracted annual recurring revenue (including forthcoming contracted installations) now stands at £0.7m, compared with £0.3m at the same time last year (+133%).

Cash

Group net cash was approximately £3.0m at 31 October 2017 (31 July 2017: £2.0m; 31 January 2017: £1.0m) following the initial proceeds from the Sheen Instruments disposal of £1.1m in October. The net cash position has also been impacted by investment in working capital of approximately £0.4m as a result of the strong trading performance in this quarter.

John Wilson, Chief Executive Officer of Elektron, said:

"Q3 trading has been strong. The Board now expects full year performance to be ahead of its previous expectations."

Enquiries:

 

Elektron Technology plc 

www.elektron-technology.com

 

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

 

Andy Weatherstone - Chief Financial Officer & Company Secretary

 

 

 

finnCap (Nominated Adviser & Broker)

+44 (0)20 7220 0500

Ed Frisby / Scott Mathieson - Corporate Finance

 

Abigail Wayne - Corporate Broking

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

Elektron conceives designs and markets innovative engineered products and services for businesses that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

- Demand for ubiquitous power and data: Bulgin

- New waves of "aware" business applications: Checkit

- The effect of ageing on sight: Elektron Eye Technology

- Growth in high precision manufacture: Queensgate

 

Cautionary statement

This financial information has been prepared only for the shareholders of Elektron as a whole and its sole purpose and use is to assist shareholders to exercise their governance rights. Elektron and its Directors and employees are not responsible for any other purpose or use or to any other person in relation to this report.

The report contains indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. Key risks and their mitigation have not changed materially in the period from those disclosed on pages 12 to 14 of the annual financial statements for the year ended 31 January 2017.

These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBUBDBCSGBGRB
Date   Source Headline
10th Aug 20237:00 amRNSTrading update notice of results & contract
8th Jun 20234:08 pmRNSResult of AGM
24th May 20233:29 pmRNSDirector/PDMR Shareholding
15th May 20231:04 pmRNSPosting of Annual Report and Notice of AGM
24th Apr 20237:00 amRNSPreliminary Results
13th Apr 20231:36 pmRNSNotice of Results and Investor Presentation
23rd Mar 20235:25 pmRNSDirector/PDMR Shareholding
13th Mar 20238:55 amRNSStatement re. Silicon Valley Bank
16th Feb 20237:00 amRNSTrading Update and Notice of Results
26th Jan 20234:10 pmRNSDirectorate Change
23rd Jan 20237:00 amRNSDirector/PCA Dealing
10th Jan 20237:00 amRNSAppointment of Non-Executive Director
10th Jan 20237:00 amRNSGrant of options and PDMR dealings
5th Jan 20237:00 amRNSContract wins and investor presentation
12th Dec 20225:14 pmRNSDirector/PDMR Shareholding
27th Sep 202212:28 pmRNSHolding(s) in Company
23rd Sep 20226:16 pmRNSDirector/PDMR Shareholding
16th Sep 20225:36 pmRNSDirector Dealing
15th Sep 20227:00 amRNSInterim Results
6th Sep 20227:00 amRNSInvestor Presentation
22nd Aug 20221:07 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSTrading Update and Notice of Interim Results
9th Jun 20223:09 pmRNSResult of AGM
13th May 20225:17 pmRNSPosting of Annual Report and Notice of AGM
13th May 20227:00 amRNSInvestor Conference
4th May 20227:00 amRNSContract Renewal
28th Apr 20227:00 amRNSPreliminary Results
29th Mar 20227:00 amRNSGrant of options and PDMR dealings
23rd Feb 20227:00 amRNSPDMR Dealing
22nd Feb 20227:00 amRNSPDMR Dealing
17th Feb 20227:00 amRNSTrading update
1st Feb 20227:00 amRNSContract win
22nd Dec 20212:06 pmRNSHolding(s) in Company
20th Dec 20217:01 amEQSCheckit (CKT): SaaS software for the deskless workforce
17th Dec 20212:44 pmRNSDirector/PDMR Shareholding
16th Dec 202111:52 amRNSResult of General Meeting and Admission
2nd Dec 202111:00 amRNSHolding(s) in Company
2nd Dec 202111:00 amRNSHolding(s) in Company
29th Nov 202111:44 amRNSPosting of Circular and Notice of General Meeting
26th Nov 20212:23 pmRNSResult of Placing
26th Nov 20217:00 amRNSProposed Placing
28th Oct 20217:00 amRNSContract win
16th Sep 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSTrading Update and Notice of Interim Results
6th Aug 20213:13 pmRNSDirector/PDMR Shareholding
15th Jul 20217:00 amRNSProduct Update
13th Jul 20215:08 pmRNSGrant of options and PDMR dealings
12th Jul 20217:00 amRNSAppointment of Chief Executive Officer
29th Jun 20214:01 pmRNSCapital Markets Day
10th Jun 20219:16 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.